Florbetaben (18F)

• A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into… Not authorised
  2022-501644-15-00 Phase II 11 countries Biogen Idec Research Limited
• An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting
  2024-518006-40-00 Phase III 6 countries F. Hoffmann-La Roche AG
• A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheime… Recruiting
  2023-509807-34-00 Phase II 3 countries Acumen Pharmaceuticals Inc.
• A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting
  2024-518008-33-00 Phase III 7 countries F. Hoffmann-La Roche AG
• Patient- and care-related benefits of amyloid PET imaging (ENABLE) Recruiting
  2023-503705-10-00 Phase IV 1 country Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.
• A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) to non-invasively diagnose cardiac… Recruiting
  2024-517942-33-03 Phase III 1 country Fondazione Toscana Gabriele Monasterio
• A phase 1b/2, multicenter, adaptive, double-blind, randomized, placebo-controlled study to assess the safety, tolerability, immunogenicity, … Recruiting
  2022-500069-29-00 Phase I/II 1 country AC Immune S.A.
• A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim… Ended
  2023-506183-13-00 Phase II 6 countries F. Hoffmann-La Roche AG
• A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe… Ended
  2022-501644-15-01 Phase II 11 countries Biogen Idec Research Limited
• EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended
  2023-505083-11-01 Phase II 8 countries Glaxosmithkline Research & Development Limited
• Efficacy of [18F]florbetaben PET for diagnosis of cardiac AL amyloidosis Ended
  2022-500186-27-00 Phase III 2 countries Lantheus Germany GmbH
• A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended
  2023-506170-12-00 Phase II 7 countries UCB Biopharma
• A Phase 2 Trial Evaluating the Effects of Thiethylperazine as diagnostic tool and therapeutic agent in Patients Diagnosed with an Early Stag… Ended
  2022-501137-23-00 Phase II 1 country Immungenetics AG
• A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer’s Disease (TRAILBLAZER-ALZ 6) Ended
  2022-502268-18-00 Phase III 1 country Eli Lilly & Co.

Showing 1–14 of 14 trials